Fatigue in the diaphragm may contribute to breathing issues in people with spinal muscular atrophy, a new study reports.

The specialty pharmacy Orsini was selected as a partner to provide Itvisma, the newly approved gene therapy for people with ...

Columnist Connie Chandler gives thanks for the acts of kindness her caregivers perform — the sweet stuff that makes life so ...

The FDA's approval of SMA treatment Itvisma marks an "important moment" for the SMA community, a Novartis executive says.

The U.S. Food and Drug Administration has approved Itvisma as the first gene therapy for spinal muscular atrophy patients ...

Columnist Sherry Toh prefers holiday giving rather than receiving and making others happy, because what she wants isn't found in stores.

Spinal muscular atrophy, or SMA, is a genetic disorder that is divided into five main types. Historically, people were categorized based on the age at which symptoms first appear, but now, in the ...

Spinal muscular atrophy (SMA) is a rare genetic condition characterized by progressive muscle weakness and atrophy. It mainly affects motor function, but often also causes problems with speaking, ...

Type 1 spinal muscular atrophy (SMA), also called infantile-onset SMA or Werdnig-Hoffmann disease, is the most common form of SMA, accounting for about 60% of cases. SMA is a rare genetic disease ...

There are several treatment options available for spinal muscular atrophy (SMA), a rare genetic condition characterized by progressive muscle weakness and wasting. The disease mainly affects motor ...

Type 3 is a milder form of spinal muscular atrophy (SMA), a rare genetic disease characterized by the progressive loss of motor neurons, the nerve cells that control voluntary movement. SMA results in ...